ArticleThe Journal of antibiotics2023
Antibacterial and antibiofilm activities of ZIF-67.
Article in The Journal of antibiotics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 60 citations in OpenAlex.
- ZIF-67 and Mn & Zn co-doped ZIF-67 as multifunctional therapeutic platforms: Antibacterial, antioxidant, and anticancer assessment in lung cancer cellsBiomaterials and biosystems · 2026Article
- Bioactive Hydrogel-MOF Composites as Resistance-Modulating Wound Interfaces: Molecular Mechanisms and Rational Design for Chronic Wound Management.Gels (Basel, Switzerland) · 2026Review
- Blue benzoquinone from scorpion venom shows bactericidal activity against drug-resistant strains of the priority pathogen Acinetobacter baumannii.The Journal of antibiotics · 2025Article
- Bio-inspired hierarchical bamboo-based air filters for efficient removal of particulate matter and toxic gases.Exploration (Beijing, China) · 2025Article
- Article
- Fingolimod Inhibits Exopolysaccharide Production and Regulates Relevant Genes to Eliminate the Biofilm ofInternational journal of molecular sciences · 2024Article
- Synthesis of Metal-Organic Framework-Based ZIF-8@ZIF-67 Nanocomposites for Antibiotic Decomposition and Antibacterial Activities.ACS omega · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, antibiotic-resistant bacteria represent a serious threat to public health worldwide. Biofilm formation potentiates both virulence and antibiotic resistance of bacteria. Therefore, the discovery of new antibacterial and antibiofilm compounds is an issue of paramount importance to combat and prevent hard-to-treat bacterial infections. Zeolitic-imidazolate-frameworks (ZIFs) are metallo-organic compounds known to have various interesting chemical and biological applications, including antibacterial properties. In this study, we synthesized ZIF-67 nanoparticles, formed by imidazolate anions and cobalt cations, and found that they inhibit the growth of Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus. Sub-inhibitory concentrations of ZIF-67 were also able to significantly reduce the biomass of pre-established biofilms of these pathogenic bacteria. On the other hand, the ZIF-67 nanoparticles had null or low cytotoxicity in mammalian cells at those concentrations showing antibacterial or antibiofilm activities. Thus, our results reveal the potential of ZIF-67 nanoparticles to be used against pathogenic bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.